Lantheus Medical Imaging®
331 Treble Cove Road
North Billerica, MA 01862
800.362.2668
www.lantheus.com

FOR IMMEDIATE RELEASE

CONTACTS:

Linda Lennox
978-671-8854

Meara Murphy
978-671-8508

Lantheus Medical Imaging Announces Xenon 133 Supply Agreement with Institute for Radioelements

Agreement Demonstrates Lantheus' Commitment to Secure Continuous Supply of Xenon 133 to U.S. Medical Market through 2016 and Beyond

No. BILLERICA, Mass. (January 21, 2015) – Lantheus Medical Imaging, Inc. (Lantheus), a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents, today announced a new strategic agreement with the Institute for Radioelements (IRE) for the future supply of Xenon Xe 133 Gas (Xenon 133). The agreement supports Lantheus' commitment to ensuring that the medical community has continued reliable access to Xenon 133 to meet the needs of patients. Presently, Lantheus is the only U.S. manufacturer of Xenon 133, which is an inhaled radiopharmaceutical imaging agent used for the evaluation of pulmonary function and for imaging the lungs, as well as the assessment of cerebral blood flow.

Under the terms of the agreement, IRE will provide bulk Xenon 133 to Lantheus for processing and finishing, once development work has been completed and all necessary regulatory approvals have been obtained. Lantheus estimates commercial production will occur in 2016.

"As the leading provider of Xenon 133, Lantheus wants to ensure that the U.S. medical market has a secure and continuous future supply of this important imaging agent, and our agreement with IRE underscores our commitment to this critical objective," said Jeff Bailey, President and CEO of Lantheus. "We look forward to working with IRE, one of the few world leaders in the production of bulk high quality medical radioisotopes, on this essential effort to provide customers and their patients access to Xenon 133 through 2016 and beyond."

“We are happy to be working with Lantheus and expanding our commitment to patients in the United States,” said Jean-Michel Vanderhofstadt, General Manager of IRE. “Providing for an uninterrupted high quality supply of Xenon 133 and molybdenum-99 are key priorities for our team as we work on a parallel path to ensure that our important LEU conversion program meets all of its technical and timeline related deliverables. We look forward to our continued work with Lantheus and our continued role in providing important medical isotopes to clinicians and patients in North America.”

About Xenon Xe 133 Gas (Xenon 133)
Xenon 133 is an inhaled radiopharmaceutical imaging agent used for the evaluation of pulmonary function and for imaging the lungs.

INDICATIONS AND USAGE:
Inhalation of Xenon 133 has proved valuable for the evaluation of pulmonary function and for imaging the lungs. It may also be applied to assessment of cerebral flow.

CONTRAINDICATIONS:
None known.

Important Safety Information:
Adverse reactions related to the use of this agent have not been reported to date.

WARNINGS:
Xenon 133 delivery systems, i.e., respirators or spirometers, and associated tubing assemblies must be leak proof to avoid loss of radioactivity into environs not specifically protected by exhaust systems.

Xenon 133 adheres to some plastics and rubber and should not be allowed in tubing or respirator containers. The unrecognized loss of radioactivity from the dose for administration may render the study non-diagnostic.

The vial stopper contains dry natural rubber latex and may cause allergic reactions in providers or patients who are sensitive to latex.

PRECAUTIONS:
General: Xenon 133, as well as other radioactive drugs, must be handled with care and appropriate safety measures should be used to minimize radiation exposure to patients and to clinical personnel. Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides.

Please see full prescribing information on www.lantheus.com.

About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc. is a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents. The Company provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. Lantheus’ key products include the

echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon Xe 133 Gas (Xenon 133), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs.

Lantheus has more than 500 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia. For more information, visit www.lantheus.com.

About the IRE
Located in Fleurus, Belgium, the Institute for Radioelements (IRE) is a public utility foundation that was created in 1971 to use nuclear technologies to improve public health and environmental control.

The IRE is one of the largest producers worldwide of radionuclides for use in nuclear medicine and exports its products throughout the world. The Institute produces radionuclides used both for imaging (early screening for malignant tumours, analysis of organ malfunction) and therapies (cancer treatment). It is also responsible for the radiological monitoring of the Belgian territory.

The IRE helps to improve the health and save the lives of millions of individuals throughout the world every year.

For more information, please visit www.ire.eu.

Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties that may be described from time to time in our filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

# # #